Ligand

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Retrieved on: 
Wednesday, October 18, 2023
Dravet syndrome, Lennox–Gastaut syndrome, Epilepsy, Growth, Seizure, LGS, Finance, SAN, Pharmaceutical industry, Takeda, Ligand

In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.

Key Points: 
  • In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.
  • “We are pleased to partner with Ligand which recognizes the potential value of our royalty and milestone payments associated with soticlestat,” said Jeffrey Rona, Chief Business and Financial Officer of Ovid.
  • With this additional, non-dilutive capital infusion from Ligand, Ovid anticipates that its cash runway is expected to last into 2026 and will enable the expansion of its clinical programs.
  • Ovid has no ongoing obligations or costs associated with the development of soticlestat.

Next Generation Drug Conjugates Market to Soar with Over 20% CAGR: Revolutionizing Rare Disease Treatment and Oncology Therapies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Pharmaceutical, Health, Oncology, Ligand, Cancer, Lipid, Antibody, USFDA, U.S.–Afghanistan Strategic Partnership Agreement, Lutetium (177Lu) oxodotreotide, LICA, Oligonucleotide, Traction, Success, Radionuclide, USD, Therapy, Janssen, Generic drug, Novartis, SMDC, FDA, AstraZeneca, Peptide, Growth, Brown sugar, Rare disease, Region, Rare, Clinical trial, PRRT, Spacecraft, N-Acetylgalactosamine, Alnylam Pharmaceuticals, Patient, Fine chemical, Pharmaceutical industry, Vaccine, Lutetium (177Lu) vipivotide tetraxetan

This growing burden of rare diseases has driven the search for alternative therapies, and next generation drug conjugates have emerged as a viable option.

Key Points: 
  • This growing burden of rare diseases has driven the search for alternative therapies, and next generation drug conjugates have emerged as a viable option.
  • Advantages Over Antibody Drug Conjugates (ADCs): Next generation drug conjugates share similarities with antibody drug conjugates (ADCs) but offer advantages in terms of clinical efficacy and stability.
  • Types of Next Generation Drug Conjugates: Various types of next generation drug conjugates have emerged, including peptide drug conjugates, peptide receptor radionuclide therapy (peptide radionuclide conjugates), GalNac conjugates, peptide oligonucleotide conjugates, si-RNA conjugates, small molecule-drug conjugates (SMDC), ligand-conjugated antisense medicine (LICA), and peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO).
  • Peptide Drug Conjugates: Peptide drug conjugates have emerged as a promising alternative to antibody drug conjugates (ADCs).

OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors

Retrieved on: 
Monday, October 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Ligand, Tumor microenvironment, Mnemos EP, Hepatocellular carcinoma, AACR, PD-L1, Communication, MTD, Preventive healthcare, Index, OSE, PD-L2, ISIN, Maxima and minima, Conference, Patient, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).
  • Silvia Comis, Head of Clinical Development and Regulatory Affairs of OSE Immunotherapeutics, comments: “These first efficacy and safety positive results from clinical Phase 1/2 assessing the therapeutic potential of our proprietary anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors are very promising.
  • These results encourage further clinical development of OSE-279 in the future as a monotherapy treatment in pre-identified cancer niche indications, with still high unmet medical needs.
  • This product will also be available for combination with other OSE drug candidates or with external assets opening new potential partnerships.”
    The communication reported on the first positive results from the Phase 1/2 clinical trial evaluating OSE-279 monotherapy in patients with advanced solid tumors, with no therapeutic option available.

GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564

Retrieved on: 
Thursday, September 28, 2023
Partnership, Neoplasm, Biotechnology, Ligand, Head, Toxicity, Infection, Bangladesh Technical Education Board, Trial of the century, Regulatory T cell, Development, National Cancer Institute, SAN, Cooperative research and development agreement, NCI, IND, Tumor microenvironment, Vaccine, Pharmaceutical industry, Grifols

SAN CARLOS, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --   GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed an agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to advance development of the company’s differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564.

Key Points: 
  • Previous anti-CTLA-4 drugs were designed to strongly block CTLA-4's interaction with its ligands, thereby enhancing T cell co-stimulation.
  • The program will draw upon the extensive infrastructure and established scientific and clinical expertise in oncology drug development from the Center for Immuno-Oncology of the NCI Center for Cancer Research.
  • As part of the agreement, the NCI will conduct the Phase 1 clinical study of GIGA-564 in advanced solid tumors.
  • Presentation details are below:
    Title: Non-clinical results and design of First-in-Human study for GIGA-564, a third-generation anti-CTLA-4 monoclonal antibody

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

Retrieved on: 
Wednesday, September 27, 2023
Biotechnology, General Health, Pharmaceutical, Health, New Drug Application, Novin, United States bankruptcy court, Bayer, Molluscum contagiosum, PDUFA, First Ever, Bankruptcy, Cryptocurrency, Ligand

On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession (“DIP”) financing.

Key Points: 
  • On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession (“DIP”) financing.
  • In September 2023, the Bankruptcy Court approved a $12.2 million bid from Ligand to purchase berdazimer gel and all the assets related to the NITRICIL™ technology platform, and the rights to the Bayer-partnered Sitavig program.
  • The approved $12.2 million bid was credited to the $15 million DIP financing, with the balance of $2.8 million and accrued interest repaid to Ligand.
  • “We are pleased with the outcome of the bankruptcy proceeding resulting in Ligand’s full ownership of berdazimer gel, NITRICIL platform and related assets.

Global Protein Purification and Isolation Market Set to Reach USD 19.08 Billion by 2030 with a CAGR of 10.86% - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 21, 2023
Retail, Fitness & Nutrition, Health, Food, Beverage, Drug discovery, Hospital, Ligand, COVID-19, Chromatography, Research, USD, Government, Compound annual growth rate, Investment, Application, Growth, R, ChromeOS, Fine chemical, Pharmaceutical industry

The global protein purification and isolation market is expected to witness remarkable growth, reaching a projected value of USD 19.08 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 10.86% over the forecast period.

Key Points: 
  • The global protein purification and isolation market is expected to witness remarkable growth, reaching a projected value of USD 19.08 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 10.86% over the forecast period.
  • However, challenges such as high purification device costs and a shortage of skilled professionals are impeding market expansion.
  • Efficiency and Speed: Rapid purification kits are becoming essential to shorten the purification and isolation process while maintaining efficacy.
  • COVID-19 Impact: The COVID-19 pandemic disrupted global supply chains and funding availability, impacting the protein purification and isolation market.

Depixus to showcase unique single molecule technology solving the hit-to-lead challenge in RNA-targeted drug discovery at upcoming Discovery on Target Conference

Retrieved on: 
Wednesday, September 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Molecule, Drug discovery, Ligand, RNA, Failure, Drug development, Conference, Pharmaceutical industry

Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA-targeted drug discovery at the upcoming Cambridge Healthtech Institute Discovery on Target Conference in Boston, USA, between 25 and 28 September 2023.

Key Points: 
  • Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA-targeted drug discovery at the upcoming Cambridge Healthtech Institute Discovery on Target Conference in Boston, USA, between 25 and 28 September 2023.
  • Progress in this space is hampered by a lack of effective methods to visualize and understand how RNA structures interact with their native ligands and candidate drugs.
  • This major limitation can result in ineffective molecules being advanced through the drug development pipeline with consequent costly failure during late preclinical or early clinical stages.
  • Based on magnetic force spectroscopy, Depixus’ MAGNA™ technology enables high-throughput single molecule analysis of molecular interactions between small molecules and target RNAs in near-real time.

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

Retrieved on: 
Monday, September 18, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, Primordial, Therapy, Enzyme, Messenger, Acquisition, Prima, Growth, Gene, Synthetic biology, Ligand, Pelican

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand,” the “Company” or “we”) announced that it has entered into a merger agreement, pursuant to which its subsidiary, Pelican Technology Holdings, Inc., (“Pelican”) has become a wholly owned subsidiary of Primrose Bio, Inc. (“Primrose Bio”, formerly known as Primordial Genetics, Inc.).

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand,” the “Company” or “we”) announced that it has entered into a merger agreement, pursuant to which its subsidiary, Pelican Technology Holdings, Inc., (“Pelican”) has become a wholly owned subsidiary of Primrose Bio, Inc. (“Primrose Bio”, formerly known as Primordial Genetics, Inc.).
  • Primrose Bio is a stand-alone private company focused on synthetic biology.
  • As part of the transaction, Ligand retains the existing commercial royalties related to the Pelican Expression Technology® and will own 49.9% of Primrose Bio.
  • Primrose Bio combines the Primordial Genetics’ Function Generator™ and Ligand’s Pelican Expression Technology® platform (formerly known as Pfenex Expression Technology®) to create a revolutionary way of enhancing biological productivity to enable the next generation of therapeutics.

Over 40 Anti TIGIT Antibodies in Clinical Trials: Unveiling the Promising Landscape of Immune Checkpoint Modulation - ResearchAndMarkets.com

Retrieved on: 
Friday, September 8, 2023
Infectious Diseases, Health, Clinical Trials, Yale University, Plastic, Construction, Electronics, ITIM, Infection, Ligand, Roche, University, NK, Compugen, Bristol Myers Squibb, AstraZeneca, CD155, Cancer, Drug discovery, TIGIT, CD112, MD Anderson Cancer Center, Nanotechnology, CD113, Vaccine, Pharmaceutical industry, Oil, BeiGene

The report provides insights into the clinical trials and market dynamics of anti TIGIT antibodies.

Key Points: 
  • The report provides insights into the clinical trials and market dynamics of anti TIGIT antibodies.
  • TIGIT (T cell immunoreceptor with Ig and ITIM domains) is an immune checkpoint protein that has gained attention as a potential therapeutic target.
  • Over 40 anti TIGIT antibodies are being evaluated in clinical trials.
  • TIGIT inhibitors are being investigated in preclinical and clinical studies, aiming to replicate the success of immune checkpoint inhibitors in various cancers.

Assessment of the Chromatography Resin Industry, 2023-2028 Featuring Profiles of Key Players Including Bio-Rad Labs, Merck, Danaher, Tosoh, Sartorius Stedim Biotech - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Biotechnology, Manufacturing, Health, Pharmaceutical, Chemicals, Plastics, FNB, GC/MS, Drink, Tosoh, Mitsubishi Chemical Corporation, Ligand, Medication, Chromatography, Merck Group, Research, Antibody, USD, Danaher Corporation, Ion exchange, Organization, Nature, Quality control, Growth, A-DNA, Food, World Health Organization, Fine chemical

This comprehensive report meticulously dissects the chromatography resin market, delving into its categorization by type, technique, application, and region, offering size predictions across diverse geographic areas.

Key Points: 
  • This comprehensive report meticulously dissects the chromatography resin market, delving into its categorization by type, technique, application, and region, offering size predictions across diverse geographic areas.
  • Chromatography has emerged as a prominent analytical technique for assessing the quality of processed food products and diverse beverages.
  • This increasing recognition of accurate analytical methods is a key driver behind the growth of the chromatography resin market.
  • Various types of synthetic or manmade polymers, including polyacrylamide, polymethacrylate, and polystyrene, serve as essential media in diverse chromatography applications.